A warning letter is FDA's position and a reply deadline, not a verdict
ON THIS PAGE
Key findings
- FDA's Regulatory Procedures Manual, Chapter 4 (Revision 12, July 2024, read October 16, 2026), says a warning letter "is informal and advisory" and that FDA does not treat it as final agency action.
- The manual says a letter usually asks for a written reply within fifteen working days of receipt. Both worked examples here, to Gram Peptides and to Tex Peptides, ask for a reply within fifteen working or business days.
- A close-out letter issues only after FDA has verified the fixes. For products sold through websites, the manual says FDA may decline to close out a letter on website changes alone.
- FDA's warning letter database lists two dates for each posted letter. The Tex Peptides letter is dated August 24, 2026 and was posted September 1, 2026.
FDA's own procedures manual answers the question in seven words: "A Warning Letter is informal and advisory." The letter tells a company where the agency stands and asks it to fix the problem. It is not a court ruling. It is not a penalty.
A warning letter in the news can read like a verdict. It is closer to a formal notice with a reply deadline. Reading it as a verdict goes wrong both ways: a letter does not prove the agency will act, and no letter does not prove a seller is clear.
What is an FDA warning letter?
It is FDA's main tool for getting a company to fix a violation on its own. The rules are in Chapter 4 of the agency's Regulatory Procedures Manual, "Advisory Actions" (Revision 12, July 2024, read on fda.gov on October 16, 2026). Section 4-1-1 says the letters "are issued to achieve voluntary compliance and to establish prior notice." They go out only for violations of "regulatory significance." The manual defines those as violations that may lead to enforcement if not promptly and adequately corrected.
The same section draws the line a reader most needs. A letter "communicates the agency's position on a matter, but it does not commit FDA to taking enforcement action." For that reason, FDA does not consider a warning letter to be final agency action on which it can be sued.
FDA's page "About Warning and Close-Out Letters" (read October 16, 2026) puts it more plainly: the letter "provides an opportunity for the company or individual to address FDA's concerns."
What a warning letter is not
A warning letter is not an enforcement action. Section 4-1-1 lists those separately: recall, seizure, injunction, administrative detention, civil money penalties and prosecution. A letter can come before any of them, and the manual notes circumstances that may keep the agency from taking any further enforcement action.
It is not a required first step either. Outside a few defined areas, the manual says, FDA has no legal duty to warn a firm before acting. A warning letter "is not a prerequisite to taking enforcement action." One case the manual names for acting without one is a violation that is "intentional or flagrant." A seller with no letter on file has not been cleared of anything. It has only not had a letter posted.
The letters this publication has already covered say this in their own words. The March 31, 2026 letter to Gram Peptides, read on fda.gov on October 16, 2026, states: "This letter notifies you of our concerns and provides you an opportunity to address them." Failing to adequately address the matter, it says, "may lead to regulatory or legal action including, without limitation, seizure and injunction." May lead.
The fifteen working day reply
A letter asks for an answer by a deadline. Section 4-1-10 lists the elements common to warning letters. Item 7 is "a request for correction and a written response within a specific period of time after the date of receipt of the letter, usually fifteen (15) working days." Item 9 says most letters should also invite a recipient that believes it is not in violation to send its reasoning and evidence.
Both worked examples follow that pattern, in slightly different words. The Gram Peptides letter asks for a reply "within fifteen working days of receipt of this letter." The August 24, 2026 letter to TXP Innovations LLC dba Tex Peptides, also read on October 16, 2026, says "within fifteen (15) business days of receipt."
The clock starts at receipt, not at posting. The Tex Peptides letter went out by email with a read and delivery receipt requested. The public could read it eight days after the date it carries.
Each letter also dates its evidence. Section 4-1-3 says a letter involving a website should state when the claims were observed. The Gram Peptides letter says FDA reviewed the site "from January to March 2026." The Tex Peptides letter names "July 2026." A letter describes a website as the agency saw it then, not as it reads today.
Untitled letters sit one step below
An untitled letter cites violations below the threshold for a warning letter, according to section 4-2-1. It has no title and no warning that enforcement may follow. It "requests (rather than requires)" a reply, and the manual's example is "Please respond within 30 days."
How a warning letter is closed out
A close-out letter says FDA has checked the fixes and accepted them. Section 4-1-8 is strict: it "will not be issued based on representations that some action will or has been taken," and the corrections "must actually have been made and verified by FDA." The usual check is a follow-up inspection.
Online sellers face a harder path. For products sold through websites, the manual says "corrective actions such as claim removal or website inactivation are reversible." FDA may not be able to inspect a seller with no physical location. The agency "may decide not to issue a close-out letter based solely on website corrections." Editing a product page is not closing the file.
Even a close-out letter is not a clean bill. It "does not relieve recipients from their responsibility" to stay compliant, and later violations may bring enforcement "without further notice."
How to find a letter and read its two dates
Posted letters are listed in FDA's warning letter database on fda.gov (content current as of October 13, 2026, read October 16, 2026). Each row gives the letter itself two dates: a Posted Date and a Letter Issue Date. It also names the company, the issuing office and a subject, with columns for a Response Letter and a Closeout Letter. The issue date is the date on the letter. The posted date is when the public could see it.
On October 16, 2026, the Gram Peptides row showed an issue date of 03/31/2026 and a posted date of 04/07/2026. The Tex Peptides row showed 08/24/2026 and 09/01/2026. On both, the Response Letter and Closeout Letter columns were empty.
An empty column means nothing has been posted. It does not mean nothing was sent. Under section 4-1-8, a response is posted when the recipient asks FDA to post it and provides it electronically, and FDA "has reserved the right not to post certain responses"; a close-out notice goes up only once a close-out letter issues. Reading a blank cell as proof that a firm ignored its letter claims something the database does not show.
The subject column is an index label, not the charge. The database files the Tex Peptides letter under "Unapproved New Drugs/Misbranded." The letter itself carries one violation subheading: "Unapproved New Drug Violations." Quote the letter, not the label.
Letters also stay up. Section 4-1-8 says FDA "does not remove Warning Letters from its Internet site unless the Agency rescinds or amends the letter."
Limitations
This piece reads the manual as FDA's account of its own practice, not as law, and says nothing about how a court would treat a letter. A later revision could change any procedure quoted here. Nothing here describes either firm's website today, any reply either firm sent, or any action after posting.
A warning letter opens a file. The Closeout Letter column is where a closed one shows up.
Sources
All read 2026-10-16 at fda.gov. Regulatory Procedures Manual, Chapter 4, Advisory Actions, Revision 12, July 2024, sections 4-1-1, 4-1-3, 4-1-8, 4-1-10 and 4-2-1. About Warning and Close-Out Letters, content current as of 2024-03-20. Warning Letters database, content current as of 2026-10-13. Gram Peptides, MARCS-CMS 721806, dated March 31, 2026. TXP Innovations LLC dba Tex Peptides, MARCS-CMS 735067, dated August 24, 2026.
Email updates
New articles and news by email, at most once a day or once a week, whichever you pick.
Respond to this analysis
Corrections, contradictions, and anything you have seen yourself. Responses are read and checked. Verified ones become entries in the ledger or corrections to this page. Nothing posts unverified, and no response is published with anything but the handle you type, or the display name of the account you sign in with. Reporting an error, or asking for this article to come down? Use the Report form below.
Report an error or request a takedown
Reports go to the site's administrators. Nothing is removed automatically.